Presenter: Thomas Powles
Early bladder cancer, including muscle invasive and non-muscle invasive disease is prevalent and a huge cancer healthcare issue. Multimodality treatments has been employed, including chemotherapy, BCG, surgery and radiotherapy. Aggressive early disease remains lethal. The immune checkpoint inhibitors have changed treatment of metastatic disease. The biology an initial data suggests they could be even more active in early disease. The data supporting this will be discussed at the webinar.